InVivo to amend INSPIRE protocol, up to 40 new patients to participate; shares slump 6% on efficacy implications [Seeking Alpha]
InVivo Therapeutics Holdings Corp. (NVIV)
Last invivo therapeutics holdings corp. earnings: 5/7 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
invivotherapeutics.com/investor-relations/press-releases
Company Research
Source: Seeking Alpha
Thinly traded micro cap InVivo Therapeutics ( NVIV ) eases on modestly higher volume in response to its announcement that it intends to amend the protocol for the Phase 3 INSPIRE study evaluating its Neuro-Spinal Scaffold in patients with acute spinal cord injury. The company says the change will allow the recruitment of an additional 20 - 40 patients who were initially rejected because they did not meet all the inclusion criteria. It plans to submit the amended protocol to the FDA this quarter. Frequently, a study sponsor increases enrollment when interim data aren't as robust as desired. According to ClinicalTrials.gov, the estimated final data collection date for the primary efficacy endpoint is June, which InVivo says will not change due to the additional treatment arm. Now read: Ingrezza Label Gives Neurocrine A Competitive Edge »
Show less
Read more
Impact Snapshot
Event Time:
NVIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVIV alerts
High impacting InVivo Therapeutics Holdings Corp. news events
Weekly update
A roundup of the hottest topics
NVIV
News
- InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
NVIV
Sec Filings
- 2/14/24 - Form SC
- 2/13/24 - Form SC
- 2/7/24 - Form 4/A
- NVIV's page on the SEC website